How medicines are managed during targeted radioligand cancer treatment
Official title: Development and Evaluation of Clinical Radiopharmacy in the Pharmaceutical Management of Patients Treated With Targeted Radionuclide Therapy (TRT) Within Nuclear Medicine Departments
Run by Hospices Civils de Lyon · NCT07389512 · Data updated 2026-11-12
This project tracks how pharmacists and nuclear medicine teams manage medications and provide pharmaceutical advice for adults receiving targeted radioligand treatments like Lutathera and Pluvicto.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 600 (estimated) |
| Sponsor | Hospices Civils de Lyon Academic / other |
| Locations | 3 sites (Bron and 2 other locations) |
| Status | Recruiting |
| Started | January 9, 2026 |
| Main results expected | September 30, 2026 |
| Study ends | September 30, 2029 |
| Registry record updated | February 5, 2026 |
| Trial ID | NCT07389512 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adult patients treated in participating nuclear medicine departments who receive pharmaceutical validation for their first TRT or who have a pharmaceutical intervention for any TRT course are eligible.
✕Probably not a fit
Minors and patients who do not receive a pharmaceutical intervention or who are treated outside the participating centers are not included and therefore would not directly benefit from the database findings.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is an observational, multicenter database collecting information on pharmaceutical validation and any pharmaceutical interventions made for adults receiving targeted radionuclide therapy (TRT). It includes patients at first TRT course and those who receive a pharmaceutical intervention for subsequent TRT courses, while excluding minors and patients without a relevant pharmaceutical intervention. Data collection will document medication reconciliation, dosing, timing, safety checks, and types and outcomes of pharmaceutical interventions across participating nuclear medicine departments. The aim is to describe current practices and identify patterns that could inform safer, more consistent medication management in TRT.
Why it matters
Potential benefit: If successful, this work could reduce medication errors and improve the safety and consistency of drug use during targeted radioligand therapy.
How similar studies have gone: While therapeutic agents like Lutathera and Pluvicto have shown clear clinical benefits, formal multicenter registries focused specifically on pharmaceutical interventions in TRT are limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * All adult patients treated in nuclear medicine with pharmaceutical validation for a first Targeted Radionuclide Therapy (TRT) will be included in the database. * All patients for whom a pharmaceutical intervention (PI) has been made, whether for a first or subsequent TRT. Exclusion Criteria: * Minor patient * Patient without a pharmaceutical intervention for a treatment other than the first TRT course
Where it's running
-
Hospices Civils de Lyon
Bron, France Recruiting -
CGFL Dijon
Dijon, France Not yet recruiting -
Centre Hospitalier Universitaire de Lille
Lille, France Not yet recruiting
Study contacts
- Study coordinator: Sarah CHAIB, PharmD
- Email: Sarah.chaib@chu-lyon.fr
- Phone: + 33 (0)4 27 85 54 14
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
MRG003 added to ongoing treatment after progression in EGFR-positive advanced thyroid cancer
In this study, researchers test whether adding MRG003 to a patient’s current thyroid cancer treatment can shrink tumors for those whose cancer initially responded but later progressed.
-
JANX013 and JANX007 combo in advanced prostate cancer
A first-in-human study will test JANX013 together with JANX007 to see if this combination is safe and tolerable in adults with metastatic castration-resistant prostate cancer.
-
Selective coverage radiotherapy vs. full coverage radiotherapy for poorly differentiated and anaplastic thyroid cancer
This trial tests whether covering only the tumor-affected area with radiation is as effective as full-area coverage radiotherapy for poorly differentiated and anaplastic thyroid cancer, while aiming to reduce side effects and improve quality of life.
-
Trop-2 Targeted PET/CT for Recurrent and Metastatic Thyroid Cancer
This study tests whether a Trop-2 targeted PET/CT scan can better detect recurrent or metastatic thyroid cancer in adults than another PET/CT scan (FAPI).
-
WeChat-supported neck exercises after thyroidectomy
A telehealth program using a WeChat mini program tests if guided neck exercises after thyroid surgery help early recovery and quality of life.
-
Pralsetinib Drug Interaction Study in RET Fusion/MUTATION Positive Solid Tumors
This trial tests whether pralsetinib changes how the body processes certain medicines in adults with RET fusion- or mutation-positive advanced solid tumors.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.